Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAR445419 |
Synonyms | |
Therapy Description |
SAR445419 are allogeneic ex vivo-expanded natural killer (NK) cells, which potentially induce killing of tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR445419 | SAR 445419|SAR-445419|KDS 1001|KDS-1001|KDS1001 | SAR445419 are allogeneic ex vivo-expanded natural killer (NK) cells, which potentially induce killing of tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05712278 | Phase I | SAR445419 Cytarabine + Fludarabine | A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |